Targets › EZH1
3 programs from 3 companies in 11 trials: 7 Phase 1, 4 Phase 2; Oncology; next expected readout Jan 2028.
Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. (UniProt, Q92800)
Open in Phaseline: the race on EZH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Daiichi Sankyo | Valemetostat Tosylate EZH1/2 dual inhibitor | EZH1, EZH2, KDM1A | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell … | Mar 2028 |
| Hanmi Pharmaceutical Company | HM97662 EZH1/2 dual inhibitor | EZH1, EZH2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2028 |
| Novartis | Tulmimetostat (DZR123, CPI-0209) Dual EZH1/EZH2 inhibitor | EZH1, EZH2 | Phase 1 | Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis Fungoides | Nov 2029 |
Advanced Solid Tumor (2) Progressive Metastatic Castrate Resistant Prostate Cancer (1) Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (1) Mycosis Fungoides (1) Relapsed/Refractory Peripheral T-Cell Lymphoma (1) Non-small Cell Lung Cancer (1) Lymphoma, B-Cell (1) Castration-Resistant Prostate Carcinoma (1) Solid Tumor Malignancies (1) Advanced or Metastatic Solid Tumors (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.